We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Genfit

News List

End of the line for Genfit's experimental NASH drug pharmatimes
July 23, 2020
Genfit has announced the termination of a late-stage trial testing elafibranor for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis.
GENFIT, Terns Pharmaceuticals to Commercialize Elafibranor in China contractpharma
June 28, 2019
For treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).
FDA grants breakthrough status to Genfit’s Elafibranor pharmaceutical-technology
April 24, 2019
FDA grants breakthrough status to Genfit’s Elafibranor.
GENFIT Announces Launch of Proposed Global Offering and Nasdaq Listing firstwordpharma
March 15, 2019
GENFIT intends to grant the underwriters for the offering (the "Underwriters") a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in th
Genfit’s elafibranor hits goal in phase 2 PBC trial fiercebiotech
December 29, 2018
A phase 2 trial of Genfit’s elafibranor in primary biliary cholangitis (PBC) has hit its primary endpoint. The readout sets Genfit up to start a pivotal trial in PBC and thereby expand its late-phase pipeline beyond NASH.....